Insmed Incorporated (INSM)

USD 70.0

(-5.21%)

Market Cap (In USD)

12.52 Billion

Revenue (In USD)

305.2 Million

Net Income (In USD)

-749.56 Million

Avg. Volume

2.23 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
21.92-80.53
PE
-
EPS
-
Beta Value
1.12
ISIN
US4576693075
CUSIP
457669307
CIK
1104506
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. William H. Lewis J.D., M.B.A.
Employee Count
-
Website
https://www.insmed.com
Ipo Date
2000-06-01
Details
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.